investing.comNov 3$CC

Chemours Q3 2026 slides: pricing gains offset seasonal headwinds

Chemours (CC) reported Q3 2026 earnings of $0.21 per share, missing estimates, on revenue of $1.54B. Adjusted EBITDA met high-end guidance at $200M, driven by pricing gains in Titanium Technologies and growth in Advanced Performance Materials. Stock initially dropped 2.73% but recovered 1.9% after-hours. Net sales rose 3% YoY, while net leverage improved to 4.3x.

Original reporting

investing.com

Published Nov 3, 2026, 2:04 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 3, 2026, 2:07 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefEarnings

Primary signal

$CC

Neutral

high confidence

Mentioned

$CC

Relevance

8/10

AlphAI data visualization · based on investing.com

Decision brief

The 30-second read

$CCNeutralMed

Why it matters

Earnings miss and settlement size provide both downside risk and upside from operational execution.

Market read

The earnings release introduces new financial data and a large settlement, offering traders fresh information to price the stock.

What to watch

Free cash flow conversion and leverage reduction may improve credit metrics, attracting yield‑focused investors.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Chemours disclosed Q3 2026 results, including a $455 million settlement for PFAS liabilities and progress on strategic initiatives.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CCNeutralHigh confidence

Context

Chemours reported Q3 2026 earnings with a $0.21 EPS miss and mixed segment performance.

Expected impact

likely modest downside in pre‑market, with potential rebound if investors focus on EBITDA beat.

Evidence & confidence

First report of the earnings numbers; market already reacted with a 2.7% drop then a 1.9% after‑hours gain.

Market effects

Sector

Chemours' pricing strength in titanium may signal pricing pressure for peers in specialty chemicals.

Regional

North American segment shows resilience, while European demand remains weak.

Global

Limited to chemicals sector; no broad market move expected.

Counterpoint

What could challenge this read

The settlement and cash flow improvements could outweigh the EPS miss, supporting a buy.

Key entities

Company
Chemours
Specialty chemicals producer reporting Q3 2026 earnings.
Government
State of North Carolina
Party to a $455 million PFAS settlement with Chemours.

Read at source ← All news

$CCMed

The Chemours Co (CC) (Q3 2026) Earnings Call Highlights: Pricing Momentum and AI-Driven

The Chemours Co (CC) reported Q3 2026 earnings, highlighting pricing momentum and AI-driven demand. The company lowered its free cash flow conversion outlook to 15%-20%, citing legal settlements and working capital timing. Q4 net sales for TSS are expected to decline 15%-20% due to seasonality, with adjusted EBITDA of $105-$115 million. TT's adjusted EBITDA is guided to $60-$65 million.

finance.yahoo.comNov 5

$CCMed

Canton CC Rises 4% After SEC Staff No-Action Letter

Canton Coin (CC) rose 4% after the SEC staff issued a no-action letter viewing it as a 'digital commodity.' The letter is not binding but indicates the SEC may not pursue enforcement action over CC's issuance under described conditions. CC traded at $0.098, down 4.2% over the past week, according to CoinMarketCap.

cointelegraph.comNov 4

$CCMedAI 8/10

Chemours (CC) Q3 2026 Earnings Call Transcript

Chemours (CC) reported Q3 2026 adjusted EBITDA of $200M, above guidance. TSS saw lower demand for Opteon blends, while TT and APM exceeded expectations. The company settled litigation with North Carolina and received final approval for a New Jersey consent order. Guidance for Q4 includes seasonal declines in sales and EBITDA for TSS and TT, with APM showing growth in Performance Solutions.

finance.yahoo.comNov 3

$CCHighAI 8/10

Chemours expects 2026 adjusted EBITDA of $775M-$800M while targeting net leverage below 4.2x (NYSE:CC)

Chemours (CC) anticipates 2026 adjusted EBITDA of $775M-$800M and aims for net leverage below 4.2x, according to its Q3 2026 earnings call. The company provided these targets to investors during the call, outlining its financial expectations for the coming years.

seekingalpha.comNov 3

$CCHigh

What Chemours (CC) Said on Its Q3 Earnings Call

Chemours (CC) expects Q4 net sales to decline in high-single-digit to low-teens range and adjusted EBITDA of $60M-$65M, citing seasonality and weaker demand. APM sales rose 26% YoY, driven by AI infrastructure demand, with Q4 sales expected to increase in low- to mid-teens range. TSS faces seasonal aftermarket softness, with Q4 sales expected to decline in high-teens to low-20% range. Full-year net sales are expected to increase about 2% compared with 2025, with adjusted EBITDA of $775M-$800M.